ArticleTherapeutic advances in medical oncology2020
Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study.
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma.Thoracic cancer · 2022Pooled it
- Spread through air spaces as a marker of nonlinear evolutionary trajectories in lung cancer: implications for the 9th edition TNM classification.Journal of pathology and translational medicine · 2026Article
- Prognostic Implications of Tumor Spread Through Air Spaces in Patients with Resected Lung Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study.BMC cancer · 2026Article
- Tumor Spread through Air Spaces in Early-Stage Lung Adenocarcinoma: Surgical Implications and Patient Management Strategies.Journal of chest surgery · 2026Review
- STAS More than a Prognostic Marker-An Evolving Factor in Operative and Adjuvant Treatment Decisions in Early-Stage NSCLC.Cancers · 2026Review
- Correlations and prognostic impacts of tumor spread through airspaces in surgically resected non-small cell lung cancer: a retrospective study from Jordan.Journal of pathology and translational medicine · 2026Article
- Multidisciplinary Perspective of Spread Through Air Spaces in Lung Cancer: A Narrative Review.Cancers · 2025Review
- CT feature-based nomogram for predicting tumor spread through air spaces in stage IA lung adenocarcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Review
- Clinical implication of tumor spread through air spaces in stage IA lung adenocarcinoma: prognostic impact and association with the International Association for the Study of Lung Cancer (IASLC) grade.Translational lung cancer research · 2025Article
- STAS: New explorations and challenges for thoracic surgeons.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- CENPF (+) cancer cells promote malignant progression of early-stage TP53 mutant lung adenocarcinoma.Oncogenesis · 2025Article
- Article
- Analysis of risk factors for postoperative recurrence of stage IA lung adenocarcinoma.Frontiers in oncology · 2025Article
- Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space.Translational lung cancer research · 2024Article
- Deep learning-based detection and semi-quantitative model for spread through air spaces (STAS) in lung adenocarcinoma.NPJ precision oncology · 2024Article
- [Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Prognostic impact of spread through air spaces in patients with ≤2 cm stage IA lung adenocarcinoma.Journal of thoracic disease · 2024Article
- The effect of spread through air spaces on postoperative recurrence-free survival in patients with multiple primary lung cancers.World journal of surgical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of adjuvant chemotherapy (ACT) remains unknown for patients with stage I lung adenocarcinoma (ADC) with spread through air spaces (STAS). This study investigated the effect of adjuvant chemotherapy in stage I ADC/STAS-positive patients.
methodsA total of 3346 patients with stage I ADC from five institutions in China were identified from 2009 to 2013, of whom 1082 were diagnosed with STAS (32.3%). By using the Kaplan-Meier method and Cox proportional hazard regression model, we explored the impact of STAS on prognosis, and determined if the use of adjuvant chemotherapy was associated with improved outcomes in patients with stage I ADC/STAS-positive. A validation cohort was also included in this study.
resultsPatients with stage I ADC/STAS-positive in the primary cohort had unfavorable overall survival (OS) and disease-free survival (DFS). A multivariate Cox regression model confirmed the survival disadvantages of STAS in patients with stage I ADC [OS: hazards ratio (HR) = 1.877, 95% confidence interval (CI): 1.579-2.231;
conclusionThe presence of STAS was correlated with poor prognosis in patients with stage I ADC. Our study suggested that ACT might be considered for patients with stage IB ADC/STAS-positive and those with stage IA ADC/STAS-positive who underwent SR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.